Highest-materiality recent filing
Chain Bridge I extends senior note maturity to Nov 2026 and raises $250K via discounted notes
Extended $1.25M senior note maturity from June 30, 2026 to Nov 15, 2026; removed certain event of default.
Chain Bridge I securities downgraded from OTCQB to OTCID for public float non-compliance
OTC Markets moved Chain Bridge I's securities from OTCQB to OTCID Basic Market on Feb 12, 2026, after cure period expired.
Chain Bridge I shareholders approve extension to Nov 2026; 393K shares redeemed for ~$4.72M
Shareholders approved amendment extending deadline for initial business combination from Nov 15, 2025 to Nov 15, 2026.
Chain Bridge I issues $1.25M convertible promissory note to C/M Capital Master Fund LP
Issued unsecured, non-interest bearing promissory note for $1.25M principal; net proceeds of $1M.
Chain Bridge I extends SPAC deadline to Nov 2026 via monthly trust contributions from Fulton AC
Fulton AC to contribute $0.01 per non-redeemed public share monthly starting Nov 16, 2025.
Chain Bridge I and CommLoan sign LOI for $50M pre-money business combination; expects Nasdaq listing
Non-binding LOI between SPAC Chain Bridge I (CBRRF) and CommLoan, a commercial real estate lending tech company.
Chain Bridge I terminates auditor Frank Rimerman after $200K error, material weakness
Audit Committee terminated Frank, Rimerman effective April 4, 2025; engaged RBSM as new auditor.
Chain Bridge I terminates Phytanix Bio merger agreement; appoints RBSM as new auditor
Mutual termination of Business Combination Agreement with Phytanix Bio effective April 7, 2025.
Audit Committee determined unaudited Q3 2024 interim financial statements cannot be relied upon due to error.
Chain Bridge I delisted from Nasdaq; shareholders approve extension, 550K shares redeemed
Nasdaq will suspend trading of CBRG shares and units on Nov 19; shares to trade on OTCQB under symbol CBRRF.
Nasdaq delisting notice received Nov 12; trading suspension effective at open on Nov 19, 2024.
Nasdaq to delist Chain Bridge I; company signs non-redemption agreements to retain trust funds
Nasdaq notified Chain Bridge I on Nov 11 it will deliver delisting letter on Nov 12 because it missed the 36-month deadline to complete a business combination.
Chain Bridge I postpones EGM to Nov 14, extends redemption deadline to Nov 12
Extraordinary General Meeting postponed from Nov 8 to Nov 14, 2024 at 11:00 a.m. ET.
Chain Bridge I sponsor agrees to reimburse trust up to $100K for dissolution expenses
Sponsor Fulton AC I LLC will fund up to $100,000 to cover dissolution costs if Company liquidates.
Chain Bridge I regains compliance with Nasdaq minimum public holders rule
On Sept 13, 2024, Nasdaq notified Chain Bridge I of regained compliance with Listing Rule 5550(a)(3) (minimum 300 public holders).
CBRG files investor presentation for Phytanix Bio merger; no specific terms disclosed
Investor presentation furnished as Exhibit 99.1 on July 29, 2024 for proposed business combination.
Chain Bridge I to merge with Phytanix Bio at $58M equity value, ticker to become PHYX
Business Combination Agreement signed July 22, 2024; closing expected Q4 2024.
Phytanix Bio agreed to loan Chain Bridge I $1,590,995.12 on June 26, 2024 via unsecured non-interest bearing promissory note.
Chain Bridge I receives Nasdaq deficiency notice for failing 300 public holders minimum
Notice on June 20, 2024 for non-compliance with Nasdaq Listing Rule 5550(a)(3) requiring minimum 300 public holders.
Chain Bridge I CFO Roger Lazarus resigns; Andrew Kucharchuk appointed April 1, 2024
Roger Lazarus resigned as CFO effective April 1, 2024; will serve as advisor through end of April 2024.
Andrew Kucharchuk, age 43, succeeded Mr. Lazarus as the Company’s Chief Financial Officer, effective April 1, 2024.
On April 1, 2024, Roger Lazarus, the Chief Financial Officer of Chain Bridge I (the “Company”), notified the board of directors of the Company (the “Board”) of his resignation, effective immediately.
Max materiality 1.00 · Median 0.60 · Most common event other_material